^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ispectamab debotansine (BMS-986352)

    i
    Other names: BMS-986352, CC-99712, CC 99712
    Associations

    News

    Trials
    Company:
    Sutro Biopharma
    Drug class:
    Microtubule inhibitor, BCMA-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=160, Active, not recruiting, Celgene | Trial completion date: May 2025 --> Aug 2024 | Trial primary completion date: May 2025 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    crenigacestat (LY3039478) • ispectamab debotansine (BMS-986352)
    4ms
    A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=160, Active, not recruiting, Celgene | Trial completion date: Apr 2024 --> May 2025 | Trial primary completion date: Apr 2024 --> May 2025
    Trial completion date • Trial primary completion date
    |
    crenigacestat (LY3039478) • ispectamab debotansine (BMS-986352)
    10ms
    A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=160, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Apr 2024 | Trial primary completion date: Dec 2024 --> Apr 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    crenigacestat (LY3039478) • ispectamab debotansine (BMS-986352)